Clinical Trial Update: A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating ACR-368 in combination with low-dose gemcitabine for recurrent/metastatic head and neck squamous cell carcinoma is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ACR-368
• Gemzar (gemcitabine)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING